Key Points
- ANI Pharmaceuticals SVP Ori Gutwerg sold 3,162 shares at an average price of $77, generating $243,474. Following the transaction, Gutwerg retained 75,534 shares valued at approximately $5.82 million.
- ANI Pharmaceuticals reported quarterly EPS of $2.21, exceeding estimates of $2.04, while revenue reached $266.04 million and rose 25.8% year over year. The stock opened at $74.53, down 1.6%.
- Analysts maintain a “Moderate Buy” consensus, with five Buy ratings and three Holds and an average price target of $105.83, despite recent target-price reductions from Canaccord Genuity and Guggenheim.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the sale, the senior vice president directly owned 75,534 shares in the company, valued at $5,816,118. The trade was a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
ANI Pharmaceuticals Trading Down 1.6%
ANIP stock opened at $74.53 on Wednesday. ANI Pharmaceuticals, Inc. has a 1-year low of $70.15 and a 1-year high of $99.50. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The business's 50 day moving average is $81.00 and its 200-day moving average is $79.18. The firm has a market cap of $1.70 billion, a P/E ratio of 16.06 and a beta of 0.44.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals's revenue was up 25.8% on a year-over-year basis. During the same quarter last year, the company earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ANI Pharmaceuticals
Several institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock worth $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after buying an additional 423 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $2,706,000. Finally, Norges Bank acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $625,000. Institutional investors own 76.05% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have issued reports on ANIP. Zacks Research cut ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday. Canaccord Genuity Group dropped their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday. Weiss Ratings raised shares of ANI Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, June 23rd. Finally, Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research report on Monday. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $105.83.
View Our Latest Research Report on ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
